

UCLA

UCLA Previously Published Works

Title

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Permalink

<https://escholarship.org/uc/item/4bh7t16n>

Journal

Clinical Infectious Diseases, 75(7)

ISSN

1058-4838

Authors

Gaylis, Norman B
Ritter, Angela
Kelly, Scott A
et al.

Publication Date

2022-09-30

DOI

10.1093/cid/ciac226

Peer reviewed

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Norman B. Gaylis,¹ Angela Ritter,² Scott A. Kelly,³ Nader Z. Pourhassan,³ Meenakshi Tiwary,⁴ Jonah B. Sacha,⁴ Scott G. Hansen,⁴ Christopher Recknor,³ and Otto O. Yang^{5,6}

¹Arthritis & Rheumatic Disease Specialties, Aventura, Florida, USA; ²Center for Advanced Research & Education, Gainesville, Georgia, USA; ³CytoDyn, Vancouver, Washington, USA; ⁴Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA; ⁵Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California—Los Angeles, Los Angeles, California, USA; and ⁶Department of Microbiology, Immunology, and Molecular Genetics, University of California—Los Angeles, Los Angeles, California, USA

In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab.

Clinical Trials Registration. NCT04678830.

Keywords. CCR5; leronlimab; long COVID; immunosuppression.

“Long COVID” is characterized by chronic and often debilitating symptoms following acute coronavirus disease 2019 (COVID-19). A significant hurdle to characterizing and diagnosing long COVID is the complexity and heterogeneity of symptoms reported among sufferers; an international cohort of 3762 participants from 56 countries identified 203 symptoms (in 10 organ systems) that persisted at least 4 weeks after a confirmed diagnosis of COVID-19 [1]. In the United States, 10%–30% of the estimated 120 million people infected with severe acute respiratory syndrome coronavirus 2 may suffer long COVID; its diagnosis and management are thus an urgent health priority.

C-C chemokine receptor 5 (CCR5) plays key roles in several diseases [2]. Multiple recent genetic association studies have reported an association between CCR5 and the severity of COVID-19 [3–5]; thus, this receptor could also be involved in the pathogenesis of long COVID. Leronlimab is a

CCR5-binding humanized immunoglobulin G₄ monoclonal antibody that has been tested in extensive human trials for the treatment of human immunodeficiency virus type 1 infection [6–9] and has been suggested to improve lymphopenia, particularly CD8 T-cell levels, by resolving inappropriate inflammation in acute severe COVID-19 [10].

METHODS

Based on the hypothesis that long COVID is mediated by persisting inflammation that remains after acute COVID-19, we performed an exploratory trial in 55 individuals with long COVID. Participants (Supplementary Table 1) were randomly assigned to receive weekly subcutaneous doses of either leronlimab (700 mg) or saline placebo for 8 weeks. The demographics for these groups were relatively similar, although participants randomized to placebo were slightly older on average (51.6 years) compared with participants randomized to leronlimab (45.5 years). Changes in 24 common symptoms (Supplementary Figure 1) were compared in participants receiving either leronlimab or placebo. The primary end point was change in symptom severity through day 56 (a numerically negative change indicating improvement). All symptoms were scored as 0–4 or 0–3 (Supplementary Figure 1), and composite symptom scores were unweighted. Exploratory end points included changes in peripheral blood leukocyte CCR5 cell surface levels, immune cell phenotypes, and plasma cytokines.

RESULTS

The mean symptom score changes from baseline to the latest available time point from day 30–56 for leronlimab vs placebo were –16.0 and –12.0, respectively; adjusting for prespecified covariates, the adjusted mean difference was –1.0 (not statistically significant; Supplementary Table 2). For several symptoms, there was a numerically higher percentage of participants with reduced raw symptom scores for leronlimab compared with placebo treatment (Supplementary Figure 2), reaching borderline statistical significance without correction for multiple comparisons due to the exploratory nature of this pilot study.

Overall cell surface CCR5 levels showed significant ($P < .0001$) increases from baseline to day 56 (week 8) among leronlimab-treated participants but not placebo-treated participants (Figure 1A). When participants with symptom improvement (“responders”) were considered separately from nonresponders (Figure 1B), cell surface CCR5 levels showed significant ($P < .0001$) increases from baseline to day 56 among leronlimab-treated responders but not treated nonresponders. In contrast, placebo-recipient participants showed no significant

Received 23 September 2021; editorial decision 16 March 2022; published online 22 April 2022.

Correspondence: O. O. Yang, BSRB 173, 615 Charles E Young Drive South, Los Angeles, CA 90095 (oyang@mednet.ucla.edu).

Clinical Infectious Diseases® 2022;XX(X):1–3

© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. <https://doi.org/10.1093/cid/ciac226>




Figure 1. Percentage CCR5 levels (CD45⁺/CCR5⁺) among participants treated with leronlimab or placebo. *A*, Percentage CCR5 expressing cells in the overall leronlimab (n = 26) and placebo (n = 28) groups. *B*, Percentage CCR5 expressing cells among participants in the leronlimab and placebo groups according to participants with and without improving long coronavirus disease 2019 symptoms (14/12 and 10/18 were improved/unimproved for the leronlimab and placebo groups, respectively). The median (50th percentile; center horizontal line), interquartile range (the 25th to the 75th percentile; box), and “whiskers” (whiskers are the 0th percentile and the 100th percentile) are indicated. One data point greater than 20% (actual value of 28%) is depicted by * on the graph, but this value was included in all statistical analyses. Abbreviations: CCR5, C-C chemokine receptor 5; NS, not statistically significantly different.

difference in cell surface CCR5 levels between baseline and day 56 for both responders and nonresponders.

No differences were observed in major immune cell populations at baseline between responders and nonresponders in either the leronlimab or placebo groups (Supplementary Figure 3). However, leronlimab treatment was associated with increases in key adaptive immune cell populations (Supplementary Table 3, Supplementary Figure 4) including T cells, consistent with data from leronlimab-treated hospitalized COVID-19 patients [10], and reduced interleukin-10 and C-C chemokine ligand-2 (CCL-2) (Supplementary Figures 5 and 6).

DISCUSSION

These findings suggest an unexpected alternative mechanism for long COVID. Rather than persistent immune activation, we observed abnormal immune downmodulation, which is normalized by leronlimab. We hypothesize that this could be immune overshoot after the intense inflammation in acute COVID-19. With genetic polymorphisms reducing cell surface CCR5 levels conferring increased risk of severe COVID-19 [4], this suggests a complex role for CCR5 in balancing inflammatory and antiinflammatory effects, for example, through T regulatory cells. While leronlimab reduces the signaling of CCR5 by Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES) [11], emerging data show that leronlimab stabilizes CCR5 expression, presumably through direct binding [12, 13], which may either change the signaling or activity of other ligands, such as Monocyte Inflammatory Protein (MIP)-1 α , MIP-1 β , and/or

Monocyte Chemoattractant Protein (MCP-2), or increase the expression of other CCRs through heterodimerization [14]. While this is a small exploratory pilot study with potential confounders, our results support further research into the role of CCR5 in long COVID.

Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. The authors thank all of the study participants and their families and caregivers for participating in this trial. They are thankful for the contributions of the investigators and their dedicated staff. Editorial assistance was provided under the supervision of the authors by Neil Buss, PhD, from Medical Expressions, which was funded by CytoDyn.

Financial support. This work was supported by CytoDyn Inc. S. G. H. reports that this support included a sponsored research agreement between the Oregon Health & Science University and CytoDyn (fee for service work to perform C-C chemokine receptor 5 receptor occupancy assay).

Potential conflicts of interest. S. A. K., N. Z. P., and C. R. are officers of CytoDyn Inc and report stock options and consulting fees from CytoDyn, assistance with manuscript preparation (Medical Expressions, paid by CytoDyn), and other financial or nonfinancial interests as employees of CytoDyn. J. B. S., S. G. H., and O. O. Y. are paid consultants for CytoDyn Inc. J. B. S. reports stock options available for purchase from CytoDyn and assistance with manuscript preparation (Medical Expressions, paid by CytoDyn). S. G. H. reports stock options and receipt of leronlimab for CCR5 receptor occupancy assay from CytoDyn and assistance with manuscript preparation (Medical Expression, paid by CytoDyn). O. O. Y. reports assistance in writing the manuscript (paid by CytoDyn). M. T. reports assistance with manuscript preparation (Medical Expressions, paid by CytoDyn). N. B. G. was a principal investigator for this trial, serves on

the CytoDyn Inc Scientific Advisory Board with stock options, and reports assistance with manuscript preparation (Medical Expressions, paid by CytoDyn). A. R. was a principal investigator for this trial and worked as an employee at the Center for Advanced Research & Education, Gainesville, Georgia, which is performing a clinical research trial for CytoDyn. A. R. reports assistance with manuscript preparation (Medical Expressions, paid by CytoDyn). All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EclinicalMedicine* **2021**; 38:101019.
2. Vangelista L, Vento S. The expanding therapeutic perspective of CCR5 blockade. *Front Immunol* **2017**; 8:1981.
3. Baranova A, Cao H, Zhang F. Unraveling risk genes of COVID-19 by multi-omics integrative analyses. *Front Med (Lausanne)* **2021**; 8:738687.
4. Cantalupo S, Lasorsa VA, Russo R, et al. Regulatory noncoding and predicted pathogenic coding variants of CCR5 predispose to severe COVID-19. *Int J Mol Sci* **2021**; 22:5372.
5. Cuesta-Llavona E, Gómez J, Albaiceta GM, et al. Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity. *Int Immunopharmacol* **2021**; 98:107825.
6. Dhody K, Pourhassan N, Kazempour K, et al. PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection. *HIV Clin Trials* **2018**; 19:85–93.
7. Jacobson JM, Lalezari JP, Thompson MA, et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. *Antimicrob Agents Chemother* **2010**; 54:4137–42.
8. Jacobson JM, Saag MS, Thompson MA, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. *J Infect Dis* **2008**; 198:1345–52.
9. Jacobson JM, Thompson MA, Lalezari JP, et al. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. *J Infect Dis* **2010**; 201:1481–7.
10. Patterson BK, Seethamraju H, Dhody K, et al. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. *Int J Infect Dis* **2021**; 103:25–32.
11. Olson WC, Rabut GE, Nagashima KA, et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. *J Virol* **1999**; 73:4145–55.
12. Chang XL, Webb GM, Wu HL, et al. Antibody-based CCR5 blockade protects macaques from mucosal SHIV transmission. *Nat Commun* **2021**; 12:3343.
13. Chang XL, Wu HL, Webb GM, et al. CCR5 receptor occupancy analysis reveals increased peripheral blood CCR5+CD4+ T cells following treatment with the anti-CCR5 antibody leronlimab. *Front Immunol* **2021**; 12.
14. Mellado M, Rodríguez-Frade JM, Vila-Coro AJ, et al. Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. *EMBO J* **2001**; 20:2497–507.